Increased funding and new public health policies for sickle cell research are needed to ease the burden on low-income nations ...

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.

Ioannis Sapountzis, head of global therapeutic areas at Boehringer, said that FIBRONEER-IPF is the largest trial in IPF ...

This blog describes a typical ILD patient journey from the initial diagnosis through its long-term management to end-of-life ...

On September 17, 2024, the lord blessed Randall “Randy” Scott Hall a much-deserved poetic exit, after an acute exacerbation ...

John Edward Trube, born August 25, 1932, in Brooklyn, New York, passed away on September 19, 2024, in Peachtree City, Georgia ...

COVID-19 evolves like other common viruses and we’re grateful for updated vaccines to help prevent severe illness, ...

Delma Bryant Armstrong, age 83, of Murfreesboro, went home to be with the Lord on Tuesday, September 17, 2024 due to ...

2022 — Idiopathic pulmonary fibrosis (IPF) is an aging-associated disease caused by progressive scarring of the lungs, leading to respiratory failure and death. Therapies to treat IPF are ...

Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia ...